What is DBV Technologies?
Founded in 2002 and operating with dual headquarters in Montrouge, France, and New York, New York, DBV Technologies is a B2B enterprise dedicated to the research and development of novel medical treatments and technologies. The company's focus on scientific advancement and clinical research positions it as a key player in the global biopharmaceutical industry. DBV Technologies leverages its expertise in specialized medical and health technologies to address unmet medical needs.
How much funding has DBV Technologies raised?
DBV Technologies has raised a total of $808.3M across 9 funding rounds:
Series B
$6.6M
Series C
$25.5M
Stock Offering
$44.5M
Share Placement
$33.9M
Stock Offering
$153.7M
Share Placement
$194M
Other Financing Round
$306.9M
Stock/Share Issuance
$30M
Series B (2009): $6.6M led by Sofinnova Partners and ALK-Abello
Series C (2011): $25.5M supported by Shire Pharmaceuticals, Lundbeckfonden Ventures, Sofinnova Partners, ALK Abello, InnoBio Fund, and Alto Invest
Stock Issuance/Offering (2012): $44.5M, investors not publicly disclosed
Share Placement (2013): $33.9M backed by Lundbeckfond, Apax Partners, Innobio, ALK Abello, and Altamir
Stock Issuance/Offering (2020): $153.7M, investors not publicly disclosed
Share Placement (2022): $194M, investors not publicly disclosed
Other Financing Round (2025): $306.9M supported by Vivo Capital, Octagon Capital Group, Adage Capital Management, MPM BioImpact, Bpifrance, Surveyor Capital, Janus Henderson Investors, and Yiheng Capital
Stock/Share Issuance (2025): $30M, investors not publicly disclosed
Key Investors in DBV Technologies
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact the company's collective future.
Apax Partners
Apax Partners is a leading global private equity advisory firm that has raised approximately $80 billion in aggregate funds over more than four decades of operation. The firm is distinguished by its sector-led investment strategy, focusing exclusively on four key global industries: Tech, Services, and Internet/Consumer. Apax creates value by partnering with high-potential management teams and providing them with a specialized mix of operating skills and deep digital expertise, often referred to as their "Digital DNA" approach.
Shire Pharmaceuticals
Shire Pharmaceuticals was a global biopharmaceutical company focused on developing and marketing treatments for rare diseases and other specialized conditions. While now part of Takeda, its historical investments highlight a strategic interest in innovative therapies.
What's next for DBV Technologies?
The recent major strategic investment signals a pivotal phase for DBV Technologies, likely enabling the company to accelerate its research and development pipelines, expand its clinical trial operations, and potentially scale its commercialization efforts. As a company that has consistently sought strategic backing, this latest capital injection suggests a strong investor confidence in DBV's therapeutic innovations and its potential to impact patient care. The company's trajectory indicates a move towards further growth and market penetration within the competitive biopharmaceutical landscape.
See full DBV Technologies company page
